非小细胞肺癌患者血清HMGB1和PD-L1检测的临床分析

doi:10.3969/j.issn.1671-2587.2020.01.013

临床输血与检验 ›› 2020, Vol. 22 ›› Issue (1): 55-57.DOI: 10.3969/j.issn.1671-2587.2020.01.013

非小细胞肺癌患者血清HMGB1和PD-L1检测的临床分析

朱蓓, 方亮, 王营营

271219 山东省新泰市新汶矿业集团有限责任公司中心医院

收稿日期:2018-07-12 出版日期:2020-02-20 发布日期:2020-02-28
作者简介:朱蓓(1981-),女,山东泰安人,主管检验师,硕士,主要从事检验工作,(Tel)17862684266。

Significance of Serum HMGB1 and PD-L1 Detections in Patients with Non-small Cell Lung Cancer

ZHU Pei, FANG Liang, WANG Ying-ying

The Central Hospital of Xinwen Mining Group Co. LTD,Xintai,Shandong 271219

Received:2018-07-12 Online:2020-02-20 Published:2020-02-28

摘要/Abstract

摘要： 目的分析非小细胞肺癌(NSCLC)患者血清高迁移率族蛋白1(HMGB 1)及程序性死亡分子配体1(PD-L1)水平与NSCLC患者病理特征的关系。方法选择2016年1月~2018年1月78例NSCLC患者及48例健康自愿者为研究对象,采用酶联免疫吸附法(ELISA)检测血清HMGB 1、PD-L1表达情况,分析外周血HMGB 1及PD-L1与NSCLC临床病理特征关系。结果 NSCLC患者血清HMGB 1(6.89±1.58 ng/mL)、PD-L1(389.3±68.5 pg/mL)均出现升高,与对照组比较差异有统计学意义(P<0.001);不同病理类型NSCLC患者血清HMGB 1、PD-L1比较,NSCLC患者血清HMGB 1、PD-L1浓度在Ⅰ期~Ⅱ期、Ⅲ期、IV期依次升高。NSCLC淋巴结转移患者血清HMGB 1、PD-L1高于未转移患者,差异有统计学意义(P<0.05)。结论 NSCLC患者外周血HMGB 1、PD-L1的检测对于肿瘤侵袭性及预后判断均有重要的临床应用价值。

关键词: 非小细胞肺癌, 高迁移率族蛋白1, 程序性死亡分子配体1

Abstract: Objective To analyze the relationship between pathological features of NSCLC patients and serum high mobility group box 1 (HMGB 1) and programmed death 1 ligand 1 (PD-L1). Methods From 2016 to 2018, 78 NSCLC patients and 48 healthy volunteers were selected. The expression of serum HMGB 1 and PD-L1 was detected by ELISA, and the pathological characteristics of peripheral blood HMGB 1 and PD-L1 and NSCLC were analyzed. Results The serum HMGB 1 (6.89±1.58 ng/ml) and PD-L1 (389.3±68.5 pg/ml) in the NSCLC patients were increased (P<0.001) compared with the control (P<0.001). Comparision of HMGB 1 with PD-L1 in different pathological types of NSCLC indicated that both the serum levels of HMGB 1 and PD-L1 were gradually increased in phases I, II, III, and IV. HMGB 1 and PD-L1 were fund to be remarkably elevated in the patients with lymph node metastasis (P<0.05). Conclusion Detection of HMGB 1 and PD-L1 in the sera of NSCLC patients is clinically valuable for prediction of tumor invasiveness and prognosis.

Key words: Non-small cell lung cancer, HMGB 1, PD-L1

中图分类号:

朱蓓, 方亮, 王营营. 非小细胞肺癌患者血清HMGB1和PD-L1检测的临床分析[J]. 临床输血与检验, 2020, 22(1): 55-57.

ZHU Pei, FANG Liang, WANG Ying-ying. Significance of Serum HMGB1 and PD-L1 Detections in Patients with Non-small Cell Lung Cancer[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(1): 55-57.

参考文献

1 戚永超. 全肺切除与肺叶切除患者术后血清CD40L、TNF-α、IL-6水平及心律失常的对比研究[J].国际检验医学杂志,2018,39(2):166-168.
2 沈红良,李娜.肺癌患者血清HE4、CEA、NSE水平变化及临床诊断价值[J].检验医学与临床,2018,15(1):109-112.
3 洪娟,王冬青,殷瑞根,等.LSD1对非小细胞肺癌细胞增殖与迁移的影响[J].江苏大学学报(医学版),2018,28(1):34-38.
4 鲍彤,肖飞,刘德若,等.非小细胞肺癌合并左房瘤栓病例的手术治疗与围术期管理[J].中国肺癌杂志,2018,21(1):24-31.
5 王晓朦,陈槿,姚佳琪,等.吉非替尼联合心包灌注治疗晚期非小细胞肺癌的疗效观察[J].中国肺癌杂志,2018,21(1):37-42.
6 修雨婷,王爱馥,张奇,等.Survivin自身抗体在非小细胞肺癌中的临床意义与诊断价值[J].中国实验诊断学,2018,22(1):15-18.
7 Su Z,Wang T,Zhu H,et al.Corrigendum to "HMGB1 modulates Lewis cell autophagy and promotes cell survival via RAGE-HMGB1-Erk1/2 positive feedback during nutrient depletion"[Immunobiology 220 May(5)(2015) 539-44[J]. Immunobiology,2018,223(2):258-259.
8 Aoto K,Mimura K,Okayama H,et al.Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma[J].Oncol Rep,2018,39(1):151-159.
9 Zhang Y,Mou J,Cao L,et al.MicroRNA-142-3p relieves neuropathic pain by targeting high mobility group box 1[J]. Int J Med,2018,41(1):501-510.
10 王高雄,王炜,王艳军,等.乙肝病毒X蛋白抑制高迁移率族蛋白B1的表达和活性氧的产生[J].中华实验外科杂志,2018,35(1):69-71.
11 Berger KN,Pu JJ.PD-1 pathway and its clinical application:A 20year journey after discovery of the complete human PD-1 gene[J].Gene,2018,638:20-25.
12 吴丹,韩笑,冯靖,等.癫痫持续状态模型中高迁移率族蛋白1、N-甲基-D-天冬氨酸受体2B亚单位的表达[J].中华医学杂志,2018,98(1):51-55.
13 Gnanasekar M,Thirugnanam S,Ramaswamy K.Short hairpin RNA(shRNA) constructs targeting high mobility group box-1(HMGB1)expression leads to inhibition of prostate cancer cell survival and apoptosis[J].Int J Oncol,2009,34(2):425-431.
14 徐韶飞,聂晚频,姚凯,等.HMBG1促进血管平滑肌细胞增殖与迁移的机制研究[J[.中国普通外科杂志,2015,24(12):1703-1708.
15 陆富策. 程序性死亡因子1在病毒感染性疾病中的作用[J].中国当代儿科杂志,2018,20(1):77-82.
16 陶凯,董剑宏.程序性死亡受体1及其配体在胃癌免疫治疗中的研究进展[J].肿瘤研究与临床,2018,30(1):69-72.
17 Cao Y,Zhang L,Kamimura Y,et al.B7-H1 over-expression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin[J].Cancer Res,2011,71(4):1235-1243.

[1]	马会博, 杜晶晶. 血DAPK和MGMT DNA水平对肺癌转移的相关性[J]. 临床输血与检验, 2020, 22(1): 51-54.
[2]	武彩虹, 银广悦, 钱成荣, 田雪梅, 徐翠玲, 张维. 血清粘附分子SE-CAD、SE-SEL和sICAM-1 在肺癌诊断中的应用^*[J]. 临床输血与检验, 2017, 19(4): 382-385.
[3]	王礼法, 刘爱胜, 余树林, 施俊柱, 程文德, 刘小君. 深圳地区103例非小细胞肺癌患者EGFR基因突变分析^*[J]. 临床输血与检验, 2017, 19(3): 248-250.
[4]	刘爱胜, 郭龙华, 文艳, 刘小君, 林丽云, 房笃智. GSTM1和CYP2E1基因多态性与非小细胞肺癌遗传易感性的相关性研究^*[J]. 临床输血与检验, 2017, 19(3): 260-265.

非小细胞肺癌患者血清HMGB1和PD-L1检测的临床分析

Significance of Serum HMGB1 and PD-L1 Detections in Patients with Non-small Cell Lung Cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们